Gensenta Ilaç San. ve Tic. A.S. > About Us

1923	Privately founded as Mustafa Nevzat Laboratory in Üsküdar/İstanbul by Prof. Mustafa Nevzat Pısak who played a great role in establishing contemporary pharmacy in Turkey.
1930	Production of Pavotin ampoule containing opium alkaloids extracted from poppy seed.
1935	An injectable product of powdered insulin was manufactured for the first time in Turkey.
1957	Moved to Mecidiyeköy/İstanbul and became a joint stock company.
1961	The first enteric-coated tablet was registered in Turkey (Entersal).
1974	Start of the production of active pharmaceutical ingredients (API).
1977	Some pharmaceutical forms such as syrups, ointments, creams and dry powder suspensions were produced at the temporary building in Yenibosna/İstanbul.
1984	A dedicated production plant established in Yenibosna to manufacture finished dosage forms of penicillin-like beta-lactams (Plant I - Penicillin-like Beta-lactam Products).
1996	A dedicated production plant established in Yenibosna to manufacture finished dosage forms of cephalosporin-like beta-lactams (Plant II - Cephalosporin-like Beta-lactam Products).
2000	The API Units were moved from İzmit-Köseköy to the new modern facilities at Çayırova-Şekerpınar. In these modern facilities, Clarithromycin and Clarithromycin granules for suspension, Sulbactam Sodium, Sultamicillin Tosylate and Sultamicillin Base were produced in those years.
2003	Yenibosna Plant III, which is one of the most modern facilities in Turkey, was completed. This plant is dedicated to non-penicillin and non-cephalosporin finished dosage forms (Plant III - Other Products).
2005	MN Pharmaceuticals signed strategic partnership agreements with several leading US generic companies for marketing and sales of its products and has submitted the first ANDA dossier to FDA. This is also a “first” for the Turkish Pharmaceutical Industry. By taking the initial step in exporting finished dosage forms to US, MN Pharmaceuticals has paved the way for the other Turkish pharmaceutical companies to follow.
2006	The API and finished dosage forms facilities have been inspected and approved by FDA in November. As a result of FDA inspection, MN Pharmaceuticals has been the first Turkish Pharma Company which has been granted the FDA approval for the API and finished dosage forms.
2007	The finished dosage forms facilities have been awarded the Environment Management Systems Certificate in the scope of ISO 14001 Standards by the British Management Systems Organization BSI. In May, the first export of finished dosage forms was performed from Turkey to USA.
2008	As a result of the MHRA inspection conducted in May, MN Pharmaceuticals received the Certificate of GMP Compliance of a Manufacturer from the British Ministry of Health. The second product entered the USA market in July.
2009	The newly established and the fourth production plant of the finished dosage forms facilities, Injectable Oncolytic Products Plant was completed at the beginning of 2009. Following the certification investigation studies conducted by Turkish Standards Institute, MN Pharmaceuticals Active Pharmaceutical Ingredients Plant has been awarded the Environment Management System Certificate in the scope of TSE ISO 14001 Standards in January. The finished dosage forms facilities have been awarded the OHSAS 18001 Occupational Health and Safety Certificate which was presented by the British Management Systems Organization BSI. The finished dosage forms facilities have been inspected and approved for the fourth time by German Health authorities and EU-GMP Certificate has been granted. (First approval was received in July, 2004.)
2010	2010 The Oncolytic Products Plant was approved by the US Food and Drug Administration (FDA) in May and by the European Medicine Agency (EMEA) in July. In December, the oncolytic drugs were shipped from Turkey to USA for the first time.
2011	Plant I- Penicillin like Beta lactam Products, Plant II- Cephalosporin like Beta lactam Products and Plant III- Other Products were inspected and approved by the GCC ( Gulf Cooperation Council).
2012	As of 12.06.2012, 99.8 percent of MN Pharmaceuticals shares was acquired by Amgen.
2014	The first biosimilar production for global markets was realized.
2020	By taking the name Gensenta; Mustafa Nevzat continues to work to offer new and comprehensive solutions to more patients in a wider geography, Gensenta facilitates patients' access to medicine, and is exporting to the region that makes up 70% of its global pharma market via Turkey.